Weiqin Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Weiqin Yang has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Alfred Sze Lok Cheng
School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong, China
19 shared publications - Ka-Fai To
Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong SAR, China
18 shared publications - Anthony Wing Hung Chan
Department of Anatomical and Cellular Pathology, State Key Laboratory in Oncology in South China Prince of Wales Hospital, The Chinese University of Hong Kong Shatin Hong Kong
17 shared publications - Jingying Zhou
School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR 999077, China
17 shared publications - Wei Kang
Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China
17 shared publications - Yalin Tu
School of Biomedical Sciences, Faculty of Medicine, the Chinese University of Hong Kong, Hong Kong SAR, People's Republic of China
17 shared publications
Latest Publications
- Open Access
- 13 December 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1)
Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and has limited therapeutic options. Epigenetic dysregulation plays a crucial role in hepatocarcinogenesis; however, its impact on cis-regulatory elements (CREs) and retrotransposons remains underexplored. Here, we investigated the epigenetic changes underlying the aberrant CRE and retrotransposon activity in HCC. We show that focal DNA hypomethylation of these elements is associated with transcriptional reprogramming. Notably, we uncover a dual regulatory mechanism for GPC3, a key diagnostic biomarker and immunotherapeutic target in HCC. This requires the concomitant reactivation of a fetal liver super-enhancer (SE) and DNA hypomethylation of CpG islands. Furthermore, DNA methylation loss drives cryptic activation of retrotransposons, some of which exhibit prognostic potential. Intriguingly, we identify a HERVE-int-derived long non-coding RNA that shows higher expression in patients with more aggressive tumors, poorer disease outcomes, and is correlated with molecular signatures associated with improved response to immunotherapy. Collectively, our findings reveal widespread epigenomic dysregulation of CREs and retrotransposons in HCC, highlighting new potential therapeutic strategies and biomarkers.
- 13 December 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1)
Open AccessMulti-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and has limited therapeutic options. Epigenetic dysregulation plays a crucial role in hepatocarcinogenesis; however, its impact on cis-regulatory elements (CREs) and retrotransposons remains underexplored. Here, we investigated the epigenetic changes underlying the aberrant CRE and retrotransposon activity in HCC. We show that focal DNA hypomethylation of these elements is associated with transcriptional reprogramming. Notably, we uncover a dual regulatory mechanism for GPC3, a key diagnostic biomarker and immunotherapeutic target in HCC. This requires the concomitant reactivation of a fetal liver super-enhancer (SE) and DNA hypomethylation of CpG islands. Furthermore, DNA methylation loss drives cryptic activation of retrotransposons, some of which exhibit prognostic potential. Intriguingly, we identify a HERVE-int-derived long non-coding RNA that shows higher expression in patients with more aggressive tumors, poorer disease outcomes, and is correlated with molecular signatures associated with improved response to immunotherapy. Collectively, our findings reveal widespread epigenomic dysregulation of CREs and retrotransposons in HCC, highlighting new potential therapeutic strategies and biomarkers.
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S1 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S1 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S14 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S14 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S14 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S14 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S7 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S7 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S13 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S13 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S13 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S13 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S3 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S3 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S8 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S8 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S12 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S12 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S12 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S9 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S9 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S9 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S4 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Figure S4 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors